MARKET

DARE

DARE

Dare Bioscience Inc
NASDAQ
0.5499
-0.0241
-4.20%
After Hours: 0.5493 -0.0006 -0.11% 19:53 03/01 EST
OPEN
0.5800
PREV CLOSE
0.5740
HIGH
0.5899
LOW
0.5400
VOLUME
576.27K
TURNOVER
0
52 WEEK HIGH
1.150
52 WEEK LOW
0.2700
MARKET CAP
54.20M
P/E (TTM)
-1.1413
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DARE last week (0219-0223)?
Weekly Report · 6d ago
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
First Lady Jill Biden announced $100 million in federal funding for research and development for women's health. The initiative is part of the White House Initiative on Women's Health Research. The funding stems from the Advanced Research Projects Agency for Health in 2022. Biden highlighted the lack of research into women's issues as a concern.
Benzinga · 02/21 17:24
Weekly Report: what happened at DARE last week (0212-0216)?
Weekly Report · 02/19 10:18
Weekly Report: what happened at DARE last week (0205-0209)?
Weekly Report · 02/12 10:12
Weekly Report: what happened at DARE last week (0129-0202)?
Weekly Report · 02/05 10:16
Buy Rating Affirmed: Daré Bioscience’s Regulatory Progress and Strategic Financing Underpin Future Growth
Daré Bioscience is developing a topical Sildenafil cream for female sexual arousal disorder (FSAD) The FDA meeting with the FDA resulted in a positive outcome for the company’s product. The company has been bolstered by a royalty financing agreement to address a significant unmet medical need.
TipRanks · 02/01 20:16
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Elevai Labs (NASDAQ:ELAB) stock is rocketing more than 76% alongside heavy pre-market trading. A private placement, direct listing, earnings reports, a public offering and more are moving stocks this morning. Check out the biggest pre- market stock movers for Thursday morning.
Investorplace · 02/01 12:38
Buy Rating Affirmed: Daré Bioscience’s Promising Market Potential and Positive FDA Engagement
TipRanks · 02/01 11:17
More
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).

Webull offers Dare Bioscience Inc stock information, including NASDAQ: DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.